RECEIVED 1643

NOV 0 2 2000

PATENT

I hereby certify that on the date specified below this correspondence is being reposited with the United States Postal Service as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

October 27, 2000

Date

John T. Oliye

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Stephen C. Goshorn et al.

Application No.

09/589,870

Filed

June 5 2000

For

STREPTAVIDIN EXPRESSED GENE FUSIONS AND METHODS

OF USE THEREOF

Art Unit

1643

Docket No.

690022,547

Assistant Commissioner for Patents Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:jto

Enclosures:

Postcard Forms PTO-1449 (8 Sheets) Cited References (88)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

L:\690022 - NeoRx\547\IDS\dscl